On the other hand, research in parallel over the same period has showcased that the same processes—MetS, DNL, dyslipidemia, MASLD, and cardiovascular disease (CVD)—may occur as decreased activity of AMP-activated protein kinase (AMPK), whose physiological role would curb these anabolic processes and instead promote catabolic, energy-producing pathways [11,12,13,14,15,16]. The gene discussed is PRKAA2; the disease is metabolic syndrome.